Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies

Abstract

Key Points Question What percentage of trials involving chimeric antigen receptor (CAR) therapy are randomized clinical trials or seek to optimize outcomes with commercially available CAR therapies? Findings In this systematic review of 778 CAR-related trials, 10 (1%) were randomized clinical trials that compared CAR therapies with non-CAR therapies. Twenty-eight trials (4%) sought to optimize the efficacy, safety, or postrelapse outcomes with existing CAR therapies. Meaning As modern CAR therapy enters its second decade, this analysis of the CAR therapy landscape suggests that more trials are needed to convincingly demonstrate its efficacy and investigate strategies to improve its safety and efficacy.